[en] We investigated the origin and the effect of insertion D67D-THGERDLGPA within HIV-1 RT from a patient failing antiviral therapy. The insertion developed within the context of pre-existing NRTI and NNRTI mutations (M41L, L210W, T215Y and N348I). Concurrently, the NRTI mutations T69I and V118I and the NNRTI mutations K103N and Y181C were detected for the first time. High-level drug resistance (fold-changes>/=50) and a good replication capacity (87% of wild-type) were observed, significantly higher than for the previous virus without insertion. The insertion was very similar to a region within human chromosome 17 (31/34 nucleotide identity), and had already been detected independently in a Japanese HIV-1 isolate. These results suggest that a particular sequence within human chromosome 17 is prone to horizontal gene transfer into the HIV-1 RT finger subdomain. This insertion confers selective advantage to HIV-1 by its contribution to multi-drug resistance and restoration of impaired replication capacity.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Altschul S.F., Madden T.L., Schaffer A.A., Zhang J., Zhang Z., Miller W., Lipman D.J. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997, 25:3389-3402.
Andreoletti L., Weiss L., Si-Mohamed A., Piketty C., Prazuck T., Calamy G., Malkin J.E., Matta M., Mbopi-Keou F.X., Clavel F., Kazatchkine M.D., Belec L. Multidrug-resistant HIV-1 RNA and proviral DNA variants harboring new dipeptide insertions in the reverse transcriptase pol gene. J. Acquir. Immune Defic. Syndr. 2002, 29:102-104.
Auwerx J., Francois K.O., Covens K., Van Laethem K., Balzarini J. Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention. Virology 2008, 382:10-19.
Balotta C., Violin M., Monno L., Bagnarelli P., Riva C., Facchi G., Berlusconi A., Lippi M., Rusconi S., Clementi M., Galli M., Angarano G., Moroni M. Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virologic failure. J. Acquir. Immune Defic. Syndr. 2000, 24:232-240.
Bennett D.E., Camacho R.J., Otelea D., Kuritzkes D.R., Fleury H., Kiuchi M., Heneine W., Kantor R., Jordan M.R., Schapiro J.M., Vandamme A.M., Sandstrom P., Boucher C.A., van de Vijver D., Rhee S.Y., Liu T.F., Pillay D., Shafer R.W. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009, 4:e4724.
Boyer P.L., Sarafianos S.G., Arnold E., Hughes S.H. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J. Virol. 2001, 75:4832-4842.
Briones C., Mas A., Perez-Olmeda M., Altisent C., Domingo E., Soriano V. Prevalence and genetic heterogeneity of the reverse transcriptase T69S-S-X insertion in pretreated HIV-infected patients. Intervirology 2001, 44:339-343.
Brockman M.A., Tanzi G.O., Walker B.D., Allen T.M. Use of a novel GFP reporter cell line to examine replication capacity of CXCR4- and CCR5-tropic HIV-1 by flow cytometry. J. Virol. Methods 2006, 131:134-142.
Bulgheroni E., Croce F., Citterio P., Vigano O., Visona R., Sala E., Galli M., Rusconi S. Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility. J. Clin. Virol. 2004, 29:27-32.
Covens K., Dekeersmaeker N., Schrooten Y., Weber J., Schols D., Quinones-Mateu M.E., Vandamme A.M., Van Laethem K. Novel recombinant virus assay for measuring susceptibility of human immunodeficiency virus type 1 group M subtypes to clinically approved drugs. J. Clin. Microbiol. 2009, 47:2232-2242.
de Jong J.J., Goudsmit J., Lukashov V.V., Hillebrand M.E., Baan E., Huismans R., Danner S.A., ten Veen J.H., de Wolf F., Jurriaans S. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS 1999, 13:75-80.
de Oliveira T., Deforche K., Cassol S., Salminen M., Paraskevis D., Seebregts C., Snoeck J., van Rensburg E.J., Wensing A.M., van de Vijver D.A., Boucher C.A., Camacho R., Vandamme A.M. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005, 21:3797-3800.
Demeter L.M., Nawaz T., Morse G., Dolin R., Dexter A., Gerondelis P., Reichman R.C. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy. J. Infect. Dis. 1995, 172:1480-1485.
DHHS, 2014. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. Panel on Antiretroviral Guidelines for Adults and Adolescents. Department of Health and Human Services.
Duarte J.M., Sathyapriya R., Stehr H., Filippis I., Lappe M. Optimal contact definition for reconstruction of contact maps. BMC Bioinform. 2010, 11:283.
Gouy M., Guindon S., Gascuel O. SeaView version 4: a multiplatform graphical user interface for sequence alignment and phylogenetic tree building. Mol. Biol. Evol. 2010, 27:221-224.
Gulick R.M., Lalezari J., Goodrich J., Clumeck N., DeJesus E., Horban A., Nadler J., Clotet B., Karlsson A., Wohlfeiler M., Montana J.B., McHale M., Sullivan J., Ridgway C., Felstead S., Dunne M.W., van der Ryst E., Mayer H. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 2008, 359:1429-1441.
Gupta R.K., Van de Vijver D.A., Manicklal S., Wainberg M.A. Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention. Retrovirology 2013, 10:82.
Harrigan P.R., Mo T., Hirsch J., Brumme Z.L., McKenna P., Bacheler L. A 21-base pair insertion/duplication at codon 69 of the HIV type 1 reverse transcriptase in a patient undergoing multiple nucleoside therapy. AIDS Res. Hum. Retrovir. 2007, 23:895-899.
Huigen M.C., de Graaf L., Eggink D., Schuurman R., Muller V., Stamp A., Stammers D.K., Boucher C.A., Nijhuis M. Evolution of a novel 5-amino-acid insertion in the beta3-beta4 loop of HIV-1 reverse transcriptase. Virology 2007, 364:395-406.
Johnson V.A., Calvez V., Gunthard H.F., Paredes R., Pillay D., Shafer R.W., Wensing A.M., Richman D.D. Update of the drug resistance mutations in HIV-1: March 2013. Top. Antivir. Med. 2013, 21:6-14.
Kaliki V., Day N.K., Dinglasan E., James-Yarish M., Hitchcock R., Skapura D., Chinta A., Johnson L., Andreopoulos A., Rey A., Good R.A., Haraguchi S. Emergence of HIV-1 variants containing codon insertions and deletions in the beta3-beta4 hairpin loop domain of reverse transcriptase. Immunol. Lett. 2000, 74:173-175.
Kellam P., Boucher C.A., Larder B.A. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 1992, 89:1934-1938.
Kew Y., Olsen L.R., Japour A.J., Prasad V.R. Insertions into the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase reveal a role for fingers subdomain in processive polymerization. J. Biol. Chem. 1998, 273:7529-7537.
Krieger E., Koraimann G., Vriend G. Increasing the precision of comparative models with YASARA NOVA - a self-parameterizing force field. Proteins 2002, 47:393-402.
Larder B.A., Bloor S., Kemp S.D., Hertogs K., Desmet R.L., Miller V., Sturmer M., Staszewski S., Ren J., Stammers D.K., Stuart D.I., Pauwels R. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob. Agents Chemother. 1999, 43:1961-1967.
Larder B.A., Kemp S.D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989, 246:1155-1158.
Lazzarin A., Clotet B., Cooper D., Reynes J., Arasteh K., Nelson M., Katlama C., Stellbrink H.J., Delfraissy J.F., Lange J., Huson L., DeMasi R., Wat C., Delehanty J., Drobnes C., Salgo M. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 2003, 348:2186-2195.
Lobato R.L., Kim E.Y., Kagan R.M., Merigan T.C. Genotypic and phenotypic analysis of a novel 15-base insertion occurring between codons 69 and 70 of HIV type 1 reverse transcriptase. AIDS Res. Hum. Retrovir. 2002, 18:733-736.
Lukashov V.V., Huismans R., Jebbink M.F., Danner S.A., de Boer R.J., Goudsmit J. Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs. AIDS Res. Hum. Retrovir. 2001, 17:807-818.
Madruga J.V., Berger D., McMurchie M., Suter F., Banhegyi D., Ruxrungtham K., Norris D., Lefebvre E., de Bethune M.P., Tomaka F., De Pauw M., Vangeneugden T., Spinosa-Guzman S. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007, 370:49-58.
Mas A., Parera M., Briones C., Soriano V., Martinez M.A., Domingo E., Menendez-Arias L. Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. EMBO J. 2000, 19:5752-5761.
Masquelier B., Race E., Tamalet C., Descamps D., Izopet J., Buffet-Janvresse C., Ruffault A., Mohammed A.S., Cottalorda J., Schmuck A., Calvez V., Dam E., Fleury H., Brun-Vezinet F. Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors. Antimicrob. Agents Chemother. 2001, 45:1836-1842.
Matamoros T., Franco S., Vazquez-Alvarez B.M., Mas A., Martinez M.A., Menendez-Arias L. Molecular determinants of multi-nucleoside analogue resistance in HIV-1 reverse transcriptases containing a dipeptide insertion in the fingers subdomain: effect of mutations D67N and T215Y on removal of thymidine nucleotide analogues from blocked DNA primers. J. Biol. Chem. 2004, 279:24569-24577.
Menendez-Arias L. Molecular basis of human immunodeficiency virus drug resistance: an update. Antivir. Res. 2010, 85:210-231.
Meyer P.R., Lennerstrand J., Matsuura S.E., Larder B.A., Scott W.A. Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation. J. Virol. 2003, 77:3871-3877.
Miyoshi I., Yoshimoto S., Kubonishi I., Taguchi H., Shiraishi Y., Ohtsuki Y., Akagi T. Transformation of normal human cord lymphocytes by co-cultivation with a lethally irradiated human T-cell line carrying type C virus particles. Gann 1981, 72:997-998.
Morcos F., Pagnani A., Lunt B., Bertolino A., Marks D.S., Sander C., Zecchina R., Onuchic J.N., Hwa T., Weigt M. Direct-coupling analysis of residue coevolution captures native contacts across many protein families. Proc. Natl. Acad. Sci. USA 2011, 108:E1293-E1301.
Onafuwa-Nuga A., Telesnitsky A. The remarkable frequency of human immunodeficiency virus type 1 genetic recombination. Microbiol. Mol. Biol. Rev. 2009, 73:451-480.
Prado J.G., Franco S., Matamoros T., Ruiz L., Clotet B., Menendez-Arias L., Martinez M.A., Martinez-Picado J. Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215. Virology 2004, 326:103-112.
Princen K., Hatse S., Vermeire K., De Clercq E., Schols D. Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists. Retrovirology 2004, 1:2.
Quinones-Mateu M.E., Tadele M., Parera M., Mas A., Weber J., Rangel H.R., Chakraborty B., Clotet B., Domingo E., Menendez-Arias L., Martinez M.A. Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation. J. Virol. 2002, 76:10546-10552.
Rakik A., Ait-Khaled M., Griffin P., Thomas T.A., Tisdale M., Kleim J.P. A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 International Study Group. J. Acquir. Immune Defic. Syndr. 1999, 22:139-145.
Ross L., Johnson M., Ferris R.G., Short S.A., Boone L.R., Melby T.E., Lanier R., Shaefer M., Clair M. Deletions in the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase are observed in HIV-1 isolated from subjects during long-term antiretroviral therapy. J. Hum. Virol. 2000, 3:144-149.
Ross L., Johnson M., Graham N., Shaefer M., Clair M. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy. J. Hum. Virol. 1999, 2:290-295.
Sato H., Shiino T., Kodaka N., Taniguchi K., Tomita Y., Kato K., Miyakuni T., Takebe Y. Evolution and biological characterization of human immunodeficiency virus type 1 subtype E gp120 V3 sequences following horizontal and vertical virus transmission in a single family. J. Virol. 1999, 73:3551-3559.
Sato H., Tomita Y., Ebisawa K., Hachiya A., Shibamura K., Shiino T., Yang R., Tatsumi M., Gushi K., Umeyama H., Oka S., Takebe Y., Nagai Y. Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase. J. Virol. 2001, 75:5604-5613.
Scherrer A.U., von Wyl V., Gotte M., Klimkait T., Cellerai C., Yerly S., Boni J., Held L., Ledergerber B., Gunthard H.F. Polymorphic mutations associated with the emergence of the multinucleoside/tide resistance mutations 69 insertion and Q151M. J. Acquir. Immune Defic. Syndr. 2012, 59:105-112.
Schneider V., Legoff J., Belec L., Delphin N., Dutreuil C., Kara-Mostefa A., Rozenbaum W., Nicolas J.C. Peptide insertions in reverse transcriptase pol gene of human immunodeficiency virus type 1 as a rare cause of persistent antiretroviral therapeutic failure. Clin. Microbiol. Infect. 2004, 10:127-136.
Shafer R.W., Kozal M.J., Winters M.A., Iversen A.K., Katzenstein D.A., Ragni M.V., Meyer W.A., Gupta P., Rasheed S., Coombs R., et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. 1994, 169:722-729.
Snoeck J., Riva C., Steegen K., Schrooten Y., Maes B., Vergne L., Van Laethem K., Peeters M., Vandamme A.M. Optimization of a genotypic assay applicable to all human immunodeficiency virus type 1 protease and reverse transcriptase subtypes. J. Virol. Methods 2005, 128:47-53.
Steigbigel R.T., Cooper D.A., Kumar P.N., Eron J.E., Schechter M., Markowitz M., Loutfy M.R., Lennox J.L., Gatell J.M., Rockstroh J.K., Katlama C., Yeni P., Lazzarin A., Clotet B., Zhao J., Chen J., Ryan D.M., Rhodes R.R., Killar J.A., Gilde L.R., Strohmaier K.M., Meibohm A.R., Miller M.D., Hazuda D.J., Nessly M.L., DiNubile M.J., Isaacs R.D., Nguyen B.Y., Teppler H. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 2008, 359:339-354.
Sugiura W., Matsuda M., Matsuda Z., Abumi H., Okano A., Oishi T., Moriya K., Yamamoto Y., Fukutake K., Mimaya J., Ajisawa A., Taki M., Yamada K., Nagai Y. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors. J. Hum. Virol. 1999, 2:146-153.
Tamalet C., Izopet J., Koch N., Fantini J., Yahi N. Stable rearrangements of the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase in plasma viruses from patients receiving combination therapy. AIDS 1998, 12:F161-F166.
Tamalet C., Yahi N., Tourres C., Colson P., Quinson A.M., Poizot-Martin I., Dhiver C., Fantini J. Multidrug resistance genotypes (insertions in the beta3-beta4 finger subdomain and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: incidence and association with other resistance mutations. Virology 2000, 270:310-316.
Tu X., Das K., Han Q., Bauman J.D., Clark A.D., Hou X., Frenkel Y.V., Gaffney B.L., Jones R.A., Boyer P.L., Hughes S.H., Sarafianos S.G., Arnold E. Structural basis of HIV-1 resistance to AZT by excision. Nat. Struct. Mol. Biol. 2010, 17:1202-1209.
van der Hoek L., Back N., Jebbink M.F., de Ronde A., Bakker M., Jurriaans S., Reiss P., Parkin N., Berkhout B. Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-acid insert in the reverse transcriptase. J. Virol. 2005, 79:3536-3543.
Van Laethem K., Schrooten Y., Covens K., Dekeersmaeker N., De Munter P., Van Wijngaerden E., Van Ranst M., Vandamme A.M. A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes. J. Virol. Methods 2008, 153:176-181.
Van Laethem K., Schrooten Y., Dedecker S., Van Heeswijck L., Deforche K., Van Wijngaerden E., Van Ranst M., Vandamme A.M. A genotypic assay for the amplification and sequencing of gag and protease from diverse human immunodeficiency virus type 1 group M subtypes. J. Virol. Methods 2006, 132:181-186.
Van Laethem K., Schrooten Y., Lemey P., Van Wijngaerden E., De Wit S., Van Ranst M., Vandamme A.M. A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene. J. Virol. Methods 2005, 123:25-34.
Van Vaerenbergh K., Van Laethem K., Albert J., Boucher C.A., Clotet B., Floridia M., Gerstoft J., Hejdeman B., Nielsen C., Pannecouque C., Perrin L., Pirillo M.F., Ruiz L., Schmit J.C., Schneider F., Schoolmeester A., Schuurman R., Stellbrink H.J., Stuyver L., Van Lunzen J., Van Remoortel B., Van Wijngaerden E., Vella S., Witvrouw M., Yerly S., De Clercq E., Destmyer J., Vandamme A.M. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob. Agents Chemother. 2000, 44:2109-2117.
White K.L., Chen J.M., Margot N.A., Wrin T., Petropoulos C.J., Naeger L.K., Swaminathan S., Miller M.D. Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations. Antimicrob. Agents Chemother. 2004, 48:992-1003.
Winters M.A., Coolley K.L., Girard Y.A., Levee D.J., Hamdan H., Shafer R.W., Katzenstein D.A., Merigan T.C. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J. Clin. Investig. 1998, 102:1769-1775.
Yap S.H., Sheen C.W., Fahey J., Zanin M., Tyssen D., Lima V.D., Wynhoven B., Kuiper M., Sluis-Cremer N., Harrigan P.R., Tachedjian G. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med. 2007, 4:e335.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
